Chen Xu, Shi Kaijia, Zhang Yi, Song Yuqi, Wang Xueyuan, Tian Xinghan
Department of Intensive Care Unit, Yantai Yuhuangding Hospital, Yantai, Shandong 264000, PR China.
Hainan Provincial Key Laboratory for Tropical Cardiovascular Disease Research, the First Affiliated Hospital, Hainan Medical University, Haikou 571199, PR China.
Clin Nutr ESPEN. 2024 Jun;61:37-45. doi: 10.1016/j.clnesp.2024.03.009. Epub 2024 Mar 12.
The evidence connecting polyunsaturated fatty acids (PUFAs) to biliary problems is still highly contested and speculative despite the fact that biliary diseases are common and PUFAs have long been studied for their potential health benefits. This work used Mendelian randomization (MR) techniques in conjunction with genome-wide association study (GWAS) data to clarify the causal relationships between PUFAs and biliary tract diseases.
We compiled data on PUFAs, including Omega-3 fatty acids, Omega-6 fatty acids, and the ratio of Omega-6 to Omega-3 fatty acids (Omega-6:Omega-3), using GWAS. MR was used to examine biliary tract problems (cholecystitis, cholelithiasis, gallbladder cancer, primary biliary cholangitis, primary sclerosing cholangitis, and disorders of gallbladder, biliary tract and pancreas). Single nucleotide polymorphisms significantly associated with PUFAs were selected as instrumental variables to estimate causal effects on biliary tract diseases. The final results were analyzed using five MR analysis techniques. Inverse variance weighting (IVW) was used as the primary outcome. And IVW was utilized in conjunction with the other MR analysis techniques (MR-Egger, weighted median, simple mode, and weighted mode). Additionally, we evaluated heterogeneity and horizontal multiplicity using the MR-Egger intercept test and Cochrane's Q test, respectively. Finally, to increase the accuracy and precision of the study outcomes, we carried out a number of sensitivity analyses.
We found that Omega-3 fatty acids reduced the risk of cholecystitis (OR: 0.851, P = 0.009), cholelithiasis (OR: 0.787, P = 8.76e-5), and disorders of gallbladder, biliary tract and pancreas (OR: 0.842, P = 1.828e-4) but increased the primary biliary cholangitis (OR: 2.220, P = 0.004). There was no significant association between Omega-3 fatty acids and risk of gallbladder cancer (OR: 3.127, P = 0.530) and primary sclerosing cholangitis (OR: 0.919, P = 0.294). Omega-6 fatty acids were associated with a reduced risk of cholecystitis (OR: 0.845, P = 0.040). However, they were not linked to an increased or decreased risk of cholelithiasis (OR: 0.878, P = 0.14), gallbladder cancer (OR: 4.670, P = 0.515), primary sclerosing cholangitis (OR: 0.993, P = 0.962), primary cholestatic biliary cholangitis (OR: 1.404, P = 0.509), or disorders of gallbladder, biliary tract and pancreas. Omega-6:Omega-3 fatty acids were linked to a greater risk of cholecystitis, cholelithiasis, and disorders of gallbladder, biliary tract and pancreas (OR:1.168, P = 0.009, OR:1.191, P = 1.60e-6, and OR:1.160, P = 4.11e-6, respectively). But (OR: 0.315, P = 0.010) was linked to a decreased risk of primary biliary cholangitis. Not linked to risk of primary sclerosing cholangitis (OR: 1.079, P = 0.078) or gallbladder cancer (OR: 0.046, P = 0.402). According to the MR-Egger intercept, our MR examination did not appear to be impacted by any pleiotropy (all P > 0.05). Additionally, sensitivity studies validated the accuracy of the calculated causation.
Inconsistent causative relationships between PUFAs and biliary tract diseases were revealed in our investigation. However, Omega-3 fatty acids were found to causally lower the risk of cholecystitis, cholelithiasis, and disorders of gallbladder, biliary tract and pancreas. Omega-3 fatty acids increased the risk of primary biliary cholangitis in a causative way. Omega-3 fatty acids with the risk of gallbladder cancer and primary sclerosing cholangitis did not have any statistically significant relationships. Omega-6 fatty acids were not significantly causally connected with the risk of cholelithiasis, gallbladder cancer, primary sclerosing cholangitis, or disorders of gallbladder, biliary tract and pancreas. However, they did play a causative role in lowering the risk of cholecystitis. Omega-6:Omega-3 fatty acids decreased the risk of primary biliary cholangitis but increased the risk of cholecystitis, gallstone disease, and disorders of gallbladder, biliary tract and pancreas. They had no effect on the risk of gallbladder cancer or primary sclerosing cholangitis. Therefore, additional research should be done to examine the probable processes mediating the link between polyunsaturated fatty acids and the risk of biliary tract diseases.
尽管胆道疾病很常见,且多不饱和脂肪酸(PUFAs)因其潜在的健康益处长期以来一直受到研究,但将PUFAs与胆道问题联系起来的证据仍存在很大争议且具有推测性。这项研究使用孟德尔随机化(MR)技术结合全基因组关联研究(GWAS)数据,以阐明PUFAs与胆道疾病之间的因果关系。
我们利用GWAS汇编了关于PUFAs的数据,包括Omega-3脂肪酸、Omega-6脂肪酸以及Omega-6与Omega-3脂肪酸的比例(Omega-6:Omega-3)。MR用于研究胆道问题(胆囊炎、胆结石、胆囊癌、原发性胆汁性胆管炎、原发性硬化性胆管炎以及胆囊、胆道和胰腺疾病)。选择与PUFAs显著相关的单核苷酸多态性作为工具变量,以估计对胆道疾病的因果效应。最终结果使用五种MR分析技术进行分析。采用逆方差加权(IVW)作为主要结果,并将IVW与其他MR分析技术(MR-Egger、加权中位数、简单模式和加权模式)结合使用。此外,我们分别使用MR-Egger截距检验和Cochrane's Q检验评估异质性和水平多重性。最后,为提高研究结果的准确性和精确性,我们进行了多项敏感性分析。
我们发现,Omega-3脂肪酸降低了胆囊炎(OR:0.851,P = 0.009)、胆结石(OR:0.787,P = 8.76e-5)以及胆囊、胆道和胰腺疾病(OR:0.842,P = 1.828e-4)的风险,但增加了原发性胆汁性胆管炎的风险(OR:2.220,P = 0.004)。Omega-3脂肪酸与胆囊癌风险(OR:3.127,P = 0.530)和原发性硬化性胆管炎风险(OR:0.919,P = 0.294)之间无显著关联。Omega-6脂肪酸与胆囊炎风险降低相关(OR:0.845,P = 0.040)。然而,它们与胆结石(OR:0.878,P = 0.14)、胆囊癌(OR:4.670,P = 0.515)、原发性硬化性胆管炎(OR:0.993,P = 0.962)、原发性胆汁性胆管炎(OR:1.404,P = 0.509)或胆囊、胆道和胰腺疾病风险的增加或降低均无关联。Omega-6:Omega-3脂肪酸与胆囊炎、胆结石以及胆囊、胆道和胰腺疾病的风险增加相关(分别为OR:1.168,P = 0.009;OR:1.191,P = 1.60e-6;OR:1.160,P = 4.11e-6)。但(OR:0.315,P = 0.010)与原发性胆汁性胆管炎风险降低相关。与原发性硬化性胆管炎风险(OR:1.079P = 0.078)或胆囊癌风险(OR:0.046,P = 0.402)无关联。根据MR-Egger截距,我们的MR检查似乎未受任何多效性影响(所有P > 0.05)。此外,敏感性研究验证了计算因果关系的准确性。
我们的研究揭示了PUFAs与胆道疾病之间不一致的因果关系。然而,发现Omega-3脂肪酸因果性地降低了胆囊炎、胆结石以及胆囊、胆道和胰腺疾病的风险。Omega-3脂肪酸因果性地增加了原发性胆汁性胆管炎的风险。Omega-3脂肪酸与胆囊癌和原发性硬化性胆管炎风险无任何统计学上的显著关系。Omega-6脂肪酸与胆结石、胆囊癌、原发性硬化性胆管炎或胆囊、胆道和胰腺疾病风险无显著因果关联。然而,它们在降低胆囊炎风险方面确实起到了因果作用。Omega-6:Omega-3脂肪酸降低了原发性胆汁性胆管炎的风险,但增加了胆囊炎、胆结石以及胆囊、胆道和胰腺疾病的风险。它们对胆囊癌或原发性硬化性胆管炎风险无影响。因此,应开展更多研究以探讨介导多不饱和脂肪酸与胆道疾病风险之间联系的可能机制。